Elan Moves Ahead With J&J Deal, But Does Biogen Really Approve?
Executive Summary
Is it over? Elan Corp. and Johnson & Johnson said Sept. 17 they successfully closed their deal to share Alzheimer disease programs
You may also be interested in...
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2009
Thanks to the return of the initial public offering and a strong market for follow-ons, money from public investors made a huge comeback during the third quarter of 2009. The merger and acquisition scorecard totaled $17.3 billion from 22 transactions--four of which topped the billion-dollar mark. And in alliances, most notable was Johnson & Johnson and Elan Corp. PLC's joint venture, which will acquire all of the assets and rights to Elan's Alzheimer's Immunotherapy Program.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2009
Thanks to the return of the initial public offering and a strong market for follow-ons, money from public investors made a huge comeback during the third quarter of 2009. The merger and acquisition scorecard totaled $17.3 billion from 22 transactions--four of which topped the billion-dollar mark. And in alliances, most notable was Johnson & Johnson and Elan Corp. PLC's joint venture, which will acquire all of the assets and rights to Elan's Alzheimer's Immunotherapy Program.
Biogen Idec Offers Profits, Buybacks, But Mixed Messages on Tysabri
The biotech says its closely-watched MS drug Tysabri helped drive better than expected profits, but admitted it might need a new safety label.